Showing results (51-60 of 77) with videos related to
Sort By:
Pageof 8
Oncology Research|January 1, 1995
Doxorubicin and cyclosporin A affect murine lymphoid cells expressing different antigenic determinantsG Zaleskis, S Verstovsek, T S Tzai, et al.Journal of Leukocyte Biology|December 1, 1994
Lipopolysaccharide and splenic tumoricidal macrophage activationS Verstovsek, G Zaleskis, D L Maccubbin, et al.Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1980
Selective imbalances of cellular immune responses by adriamycinM J Ehrke, K Ryoyama, V Tomazic, et al.Cancer Research|January 1, 1986
Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in miceM J Ehrke, D Maccubbin, K Ryoyama, et al.The Biochemical Journal|May 1, 1974
Specific inhibition of the enzymic decarboxylation of S-adenosylmethionine by methylglyoxal bis(guanylhydrazone) and related substancesA Corti, C Dave, H G Williams-Ashman, et al.Cancer Research|October 1, 1988
Role of tumor necrosis factor in macrophage activation and tumoricidal activityK F Mace, M J Ehrke, K Hori, et al.International Journal of Cancer|October 1, 1994
Ecto-5'-nucleotidase (CD73) in multidrug-resistant cell lines generated by doxorubicinP Ujházy, M Klobusická, O Babusíková, et al.Experimental Hematology|June 1, 1995
Murine splenic macrophage tumoricidal activation by cytokinesS Verstovsek, C Eppolito, P Ujhazy, et al.Cancer Research|June 1, 1982
Toxicity and pharmacokinetics of a new antifolate, 2,4-diamino-5-adamantyl-6-methylpyrimidine, in dogsS F Zakrzewski, Z Pavelic, W R Greco, et al.Oncology Research|January 1, 1993
Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomasR L Ho, D Maccubbin, G Zaleskis, et al.Pageof 8